APA (7th ed.) Citation

Miesbach, W., Halimeh, S., Platokouki, H., Podolak‐Dawidziak, M., Zdziarska, J., Korczowski, B., . . . Pabinger, I. (2024). An open‐label, multi‐centre, post‐marketing study to assess the efficacy and safety of a plasma‐derived VWF/FVIII concentrate in patients with von Willebrand disease. Haemophilia, 30(1), 236. https://doi.org/10.1111/hae.14868

Chicago Style (17th ed.) Citation

Miesbach, Wolfgang, et al. "An Open‐label, Multi‐centre, Post‐marketing Study to Assess the Efficacy and Safety of a Plasma‐derived VWF/FVIII Concentrate in Patients with Von Willebrand Disease." Haemophilia 30, no. 1 (2024): 236. https://doi.org/10.1111/hae.14868.

MLA (9th ed.) Citation

Miesbach, Wolfgang, et al. "An Open‐label, Multi‐centre, Post‐marketing Study to Assess the Efficacy and Safety of a Plasma‐derived VWF/FVIII Concentrate in Patients with Von Willebrand Disease." Haemophilia, vol. 30, no. 1, 2024, p. 236, https://doi.org/10.1111/hae.14868.